IAM Advisory LLC Acquires $1.27M Stake in Gilead Sciences

The investment firm adds to its position in the biopharmaceutical company.

Mar. 21, 2026 at 11:06am

Got story updates? Submit your updates here. ›

IAM Advisory LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company's recent SEC filing. The fund purchased 10,375 shares of the biopharmaceutical company's stock, valued at approximately $1,273,000.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. This investment by IAM Advisory LLC suggests the firm sees growth potential in Gilead's business and stock.

The details

According to the filing, IAM Advisory LLC acquired the 10,375 shares of Gilead Sciences in the fourth quarter. The purchase was valued at around $1.27 million. Other institutional investors have also been active in Gilead's stock, with Norges Bank, Invesco Ltd., and Amundi among the largest shareholders.

  • IAM Advisory LLC acquired the Gilead Sciences shares in the 4th quarter of 2025.

The players

IAM Advisory LLC

An investment management firm that acquired a new position in Gilead Sciences, Inc.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

This investment by IAM Advisory LLC underscores the continued interest in Gilead Sciences among institutional investors, who see value in the company's leading position in the biopharmaceutical industry and its growth potential.